Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IKBKB Polymorphism and Biologic Response in Psoriasis
NCT06729463Completed
- Sponsor
- South Valley University
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of adalimumab and secukinumab in psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by South Valley University. Primary endpoint: Treatment of the Psoriasis disease at 3 months. Started Dec 2024; status: completed.
02
Drugs
adalimumabsecukinumab
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06729463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729463.